Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2022 | Hepatocellular Carcinoma | Correction

Correction to: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety

Authors: Jie Mao, Shujun Liu, Min Ai, Zhuo Wang, Duowei Wang, Xianjing Li, Kaiyong Hu, Xinghua Gao, Yong Yang

Published in: Journal of Hematology & Oncology | Issue 1/2022

Excerpt

The original article [1] contained an error in Fig. 1 which has since been corrected. …

Mao J, et al. A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety. J Hematol Oncol. 2017;10:71. https://doi.org/10.1186/s13045-017-0442-y.CrossRefPubMedPubMedCentral

Title: Correction to: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety
Authors: Jie Mao
Shujun Liu
Min Ai
Zhuo Wang
Duowei Wang
Xianjing Li
Kaiyong Hu
Xinghua Gao
Yong Yang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-022-01277-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

Keynote webinar | Spotlight on antibody–drug conjugates in cancer